GPhA Enlists Further Support for Biosimilar Naming Conventions

From DCAT Value Chain Insights (VCI)

By Regulatory News posted 07-03-2014 18:18

The Generic Pharmaceutical Association (GPhA) reports that 32 organizations signed a letter calling on FDA to require biologics and biosimilars to have the same International Nonproprietary Name (INN).

“These groups understand that the INN approach to biosimilar naming has proven safe and effective in Europe, it has worked in the United States for chemical drugs and currently approved biologics, therefore it should be the standard for US biosimilars, said GPhA CEO and President Ralph G. Neas, in a statement. “The organizations who know the most about healthcare delivery agree: departing from the currently accepted INN system will not benefit patients,” said Neas. “Instead, it will upset the very systems needed to accurately dispense and track medicines, risking increased mistakes and provider confusion.”

The letter puts forth the organizations' rationale for having the same INN for biosimilars. “While we agree that it is important to gather data that allows providers to better understand how biologics and biosimilars are performing among various patient groups and to assist in the tracking of adverse events, as we mention above, we believe that the current mechanisms in place (e.g., NDC code, lot number, brand name, manufacturer, etc.) are sufficient. In addition, because adverse events and product recalls for small-molecule and biologic drugs already are successfully identified using the national drug code (NDC code) and lot number, there is no compelling evidence that biosimilars should be handled differently.”

This letter follows concerns recently raised by the National Council for Prescription Drug Programs (NCPDP), citing serious operational problems with the implementation of a system other than the currently accepted INN construct. In a letter to the FDA, NCPDP cautioned about the impact such a change would have on the standard operating procedures inherent in the healthcare system. The standards-setting organization warned FDA that, “making changes to the current databases and the SOP’s by which they are developed, maintained, and used takes time and resources. This can result in confusion, errors, and misunderstanding, resulting in a very real risk to patients, during any transition.”

Source: GPhA



Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription